Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588
In development [GID-TA10507] Expected publication date: TBC
Search results
528 results
-
-
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
In development [GID-TA10646] Expected publication date: TBC
-
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]
In development [GID-TA10614] Expected publication date: 23 June 2021
-
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
In development [GID-TA10618] Expected publication date: 23 June 2021
-
Budesonide for treating active eosinophilic oesophagitis [ID1202]
In development [GID-TA10372] Expected publication date: 23 June 2021
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: 15 December 2021
-
Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429
In development [GID-TA10512] Expected publication date: TBC
-
Lifitegrast for treating dry eye disease [ID1229]
In development [GID-TA10196] Expected publication date: TBC
-
Abicipar pegol for treating wet age-related macular degeneration ID1533
In development [GID-TA10511] Expected publication date: TBC
-
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]
In development [GID-TA10442] Expected publication date: TBC
-
Melanoma (metastatic) - talimogene laherparepvec [ID508]
In development [GID-TAG509] Expected publication date: 28 September 2016
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
In development [GID-TA10026] Expected publication date: TBC
-
Psoriasis - briakinumab (suspended) [ID65]
In development [GID-TAG412] Expected publication date: TBC
-
Osteoarthritis - naproxcinod [ID417]
In development [GID-TAG426] Expected publication date: TBC
-
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
In development [GID-TAG418] Expected publication date: TBC
-
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]
In development [GID-TAG456] Expected publication date: TBC
-
Leukaemia (acute lymphoblastic) - dasatinib [ID386]
In development [GID-TAG399] Expected publication date: TBC
-
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]
In development [GID-TAG398] Expected publication date: 01 January 2011
-
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
In development [GID-TAG414] Expected publication date: TBC
-
Diabetic foot ulcers - new treatments [ID381]
In development [GID-TAG371] Expected publication date: TBC
-
Venous leg ulcers - new treatments [ID394]
In development [GID-TAG370] Expected publication date: TBC
-
Venous thromboembolism (VTE) - ximelagatran [ID396]
In development [GID-TAG378] Expected publication date: TBC
-
Apalutamide for treating prostate cancer [ID1534]
In development [GID-TA10423] Expected publication date: 26 May 2021
-
Baricitinib for treating moderate to severe atopic dermatitis [ID1622]
In development [GID-TA10562] Expected publication date: 03 March 2021
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Short bowel syndrome - teduglutide [ID885]
In development [GID-TA10048] Expected publication date: TBC
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza [ID1537]
In development [GID-TA10559] Expected publication date: TBC
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: 25 March 2021
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: 28 April 2021
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 21 April 2021
-
Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509
In development [GID-TA10413] Expected publication date: TBC
-
Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940
In development [GID-TA10397] Expected publication date: TBC
-
Pelareorep for untreated pancreatic cancer [ID1074]
In development [GID-TA10689] Expected publication date: TBC
-
Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]
In development [GID-TA10686] Expected publication date: TBC
-
Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]
In development [GID-TA10687] Expected publication date: TBC
-
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
In development [GID-TA10427] Expected publication date: TBC
-
Tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma (ID1441)
In development [GID-TA10428] Expected publication date: 04 May 2022
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
-
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)
In development [GID-TA10435] Expected publication date: TBC
-
Omburtamab for treating relapsed neuroblastoma [ID1664]
In development [GID-TA10608] Expected publication date: TBC
-
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]
In development [GID-TA10272] Expected publication date: 14 July 2021
-
Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]
In development [GID-TA10543] Expected publication date: TBC
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352
In development [GID-TA10319] Expected publication date: TBC
-
Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]
In development [GID-TA10508] Expected publication date: TBC